Cromolyn sodium Inh Soln Rx
Generic Name and Formulations:
Cromolyn sodium 20mg/2mL; soln for inhalation.
Various generic manufacturers
Indications for Cromolyn sodium Inh Soln:
Asthma prophylaxis. Prevention of bronchoconstriction before exposure to a known precipitant (eg, exercise).
Adults and Children:
<2 years: not recommended. ≥2 years: 20mg administered by power-operated nebulizer 4 times a day. Bronchoconstriction prevention: contents of 1 amp inhaled up to 60 minutes before precipitant.
Not for treatment of acute attack. Impaired renal or hepatic function: reduce dose. Reevaluate if no improvement after 4 weeks. Avoid abrupt cessation. Discontinue if eosinophilic pneumonia occurs. Coronary artery disease or arrhythmias (Inhaler). Pregnancy (Cat.B). Nursing mothers.
Avoid use with isoproterenol during pregnancy.
Mast cell stabilizer.
Bronchospasm, throat irritation, bad taste, cough, wheezing, nasal congestion, anaphylaxis.
Formerly known under the brand name Intal.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|